AMRN Amarin Corp

RNS Number:3838W
Amarin Corporation Plc
10 May 2007



                             AMARIN CORPORATION PLC

LONDON, United Kingdom, May 10, 2007, Amarin Corporation plc ("Amarin" or
"Company") announces that it has filed with the SEC, on Form 6-K, a copy of the
script for the Company's conference call to be held at 8:30 a.m., Eastern
Daylight Time, 1:30 p.m., British Summer Time, today, May 10, 2007. On this
call, the Company will discuss its financial results for the first quarter ended
March 31, 2007 and will provide a business and pipeline update.


About Amarin


Amarin is committed to improving the lives of patients suffering from diseases
of the central nervous system.  Our goal is to be a leader in the research,
development and commercialization of novel drugs that address unmet patient
needs.


Amarin's core development pipeline includes Miraxion for several therapeutic
indications, an oral formulation of apomorphine for treating patients with
advanced Parkinson's disease, a nasal formulation of lorazepam for treating
emergency seizures and our proprietary pre-clinical combinatorial lipid program.


Amarin has its primary stock market listing in the U.S. on NASDAQ ("AMRN") and
secondary listings in the U.K. and Ireland on AIM ("AMRN") and IEX ("H2E"),
respectively.


For press releases and other corporate information, visit the Amarin website at
http://www.amarincorp.com. Information on our website does not form part of this
press release.



Contacts:

Amarin

+44 (0) 207 907 2442

Rick Stewart, Chief Executive Officer

Alan Cooke, President and Chief Financial Officer

investor.relations@amarincorp.com


Investors:

Lippert/Heilshorn & Associates, Inc.

Anne Marie Fields, +1 212 838 3777

Bruce Voss, +1 310 691 7100


Media:

Powerscourt

+44 (0) 207 250 1446

Rory Godson

Victoria Brough


Disclosure Notice:


The information contained in this document is as of May 10, 2007. Amarin assumes
no obligation to update any forward-looking statements contained in this
document as a result of new information or future events or developments. This
document contains forward-looking statements about Amarin's financial condition,
results of operations, business prospects and products in research that involve
substantial risks and uncertainties. You can identify these statements by the
fact that they use words such as "will", "anticipate", "estimate", "expect",
"project", "forecast", "intend", "plan", "believe" and other words and terms of
similar meaning in connection with any discussion of future operating or
financial performance or events. Among the factors that could cause actual
results to differ materially from those described or projected herein are the
following: the success of Amarin's research and development activities;
decisions by regulatory authorities regarding whether and when to approve
Amarin's drug applications, as well as their decisions regarding labeling and
other matters that could affect the commercial potential of Amarin's products;
the speed with which regulatory authorizations, pricing approvals and product
launches may be achieved; the success with which developed products may be
commercialized; competitive developments affecting Amarin's products under
development; the effect of possible domestic and foreign legislation or
regulatory action affecting, among other things, pharmaceutical pricing and
reimbursement, including under Medicaid and Medicare in the United States, and
involuntary approval of prescription medicines for over-the-counter use;
Amarin's ability to protect its patents and other intellectual property; claims
and concerns that may arise regarding the safety or efficacy of Amarin's product
candidates; governmental laws and regulations affecting Amarin's operations,
including those affecting taxation; Amarin's ability to maintain sufficient cash
and other liquid resources to meet its operating requirements; general changes
in International and U.S. generally accepted accounting principles; growth in
costs and expenses; and the impact of acquisitions, divestitures and other
unusual items. A further list and description of these risks, uncertainties and
other matters can be found in Amarin's Form 20-F for the fiscal year ended
December 31, 2006, filed with the SEC on March 5 2007, Amarin's statutory annual
report for the year ended 31 December, 2006 furnished on a Form 6-K to the SEC
on May 9, 2007 and in its Reports of Foreign Issuer on Form 6-K furnished to the
SEC.


Ends.


                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
STRMGGMKFGMGNZM

Amarin (LSE:AMRN)
Historical Stock Chart
From Jan 2025 to Feb 2025

Amarin (LSE:AMRN)
Historical Stock Chart
From Feb 2024 to Feb 2025